Medical Devices marketing
Marketing a device inside what you are cleared to say
What a device company may claim is set by classification, clearance status and approved indications, and it differs by market. This page is about building demand inside those limits, for a buyer that is usually a clinician and a procurement committee at the same time.
Where the money goes
The channels that earn their place here
In priority order for this business, not a menu. Anything not on this list is something we would need a specific reason to recommend.
Coverage of the searches clinicians and procurement already run
Device category terms, technique questions, compatibility and consumable searches, framework and contract queries. These are being searched now, by people inside accounts you want, and answering them factually is entirely compatible with a constrained claim set because specification and compatibility are not clinical claims.
Evidence, instructions and specification published as pages
Published studies referenced properly with population and limitations stated, instructions for use, technical specifications, compatibility matrices and service documentation. This is the content a device buyer actually reads, it is defensible because every statement traces to a source, and most competitors have it locked inside PDFs that nobody can find.
Reaching a committee rather than a specialty
The decision usually involves a clinician, a biomedical or clinical engineering view, infection prevention where relevant, finance and procurement. Targeting by role across a named account list keeps all of those people in contact with the same material, which matters when the person who wants the device is not the person who signs for it.
A site that knows which market it is being read in
Market-aware product content, clear statements of regulatory status per market, audience routing for healthcare professionals where required, and distributor coverage by country. A single global page describing a device that is cleared in one market and pending in another is a compliance problem before it is a marketing one.
Education that stays on the right side of the line
Technique explanation, workflow and training material, health economics discussion and congress-adjacent content authored by named people with disclosed affiliations. Education is where a device company can be genuinely useful without making a claim, and it is what gets a product discussed in the settings where purchasing conversations begin.
Buying behaviour
How your customers actually decide
Strategy follows this, not the other way round. Everything on this page is downstream of how the decision genuinely gets made.
- Two buyers ask different questions and both can stop the purchase. The clinician wants to know whether it works in their hands, with their technique, on their patient mix, alongside the instruments they already use. Procurement wants total cost across consumables and service, contract route, framework availability and what happens when it fails.
- Evidence carries the argument, and its type matters as much as its existence. Peer-reviewed publication, registry data and health technology assessment are weighed differently from a manufacturer-produced summary, and a well-referenced evidence page is read by both the clinical and the finance side of the decision.
- Installed base and compatibility create switching costs that outweigh product comparison. If the capital equipment is already in the room, the consumable that fits it starts several steps ahead, and the argument for change has to cover the cost of everything that has to change with it.
- Training, on-site support and service response frequently decide the outcome. A device that requires a change in technique needs somebody present for the first cases, and a clinician who has been left unsupported by a supplier before will treat that as the deciding factor.
- Access is gated by contract mechanisms before anything else. Group purchasing agreements, national or regional frameworks and tender cycles determine whether a product can be bought at all, and a device that is not on the relevant agreement is frequently not evaluable regardless of merit.
- Reimbursement and coding sit underneath everything. Where the associated procedure is not funded, or the coding is unclear, the purchase stalls for reasons that have nothing to do with the device and that marketing has to understand rather than ignore.
What usually goes wrong
Where medical device marketing tends to fail
Almost everything difficult about marketing a medical device comes from one fact: what you are permitted to say is set by the device’s classification, by its clearance, approval or certification status, and by the indications those cover — and every one of those can be different in every market you sell into.
That is not an argument for marketing timidly. It is an argument for knowing exactly where the line sits before anybody writes a word, and for building the programme out of evidence, specification, service and education rather than out of outcome claims that cannot be made.
To be explicit about scope: this page is about marketing. Nothing on it is regulatory, legal or clinical advice, and we do not decide what a client may claim.
- The website says more than the clearance covers.
- Indication creep happens gradually and almost never deliberately. A phrase written for a conference stand becomes web copy, a translated page loses a qualifier, a legacy product page survives a labelling change, and a distributor rewrites a sentence into something stronger. The result is a set of live claims that nobody currently in the building approved. A documented claim set per market, applied consistently and re-checked on a schedule, is the only thing that prevents it.
- One global site is serving markets with different approval status.
- A device may be cleared in one jurisdiction, under review in a second and not submitted in a third, and a single page cannot honestly describe all three states. Country selectors that nobody uses and interstitials that everybody clicks through are not controls. Market-aware content, explicit status statements and distributor pages by country are the practical structure, and they need to be designed in rather than retrofitted.
- Regulatory sees the copy after it has been published.
- When review is a final gate, everything arrives at it late, gets rewritten into something cautious and unreadable, and the team gradually stops proposing anything. Moving the claim boundary to the start — an agreed set of permitted statements with the evidence attached to each — turns review into a verification step. Output goes up, cycle time falls, and the reviewer stops being the person who says no.
- The content answers the clinician and ignores procurement.
- Enthusiasm from a clinical champion does not produce a purchase order. Somebody has to justify total cost over the life of the device including consumables, service and training, identify the contract route, and confirm the budget line. If none of that exists on the website, the champion has to build the case themselves from scratch, and the ones who are busy simply do not.
- Distributors publish claims you are accountable for.
- In many markets the manufacturer carries responsibility for how its device is promoted regardless of who wrote the sentence. Distributor sites, reseller listings and marketplace entries drift quickly, particularly after translation. Written claim guidance, an approved asset library that is genuinely easier to use than writing something new, and a periodic review of partner content are the controls that work in practice.
Search behaviour
What your customers are typing
Clinical and technique searches
Made by clinicians and clinical engineers. Factual, specification-led, and answerable without making any claim about outcomes.
- single use bronchoscope compatibility with existing towers
- instructions for use for surgical stapler reloads
- reprocessing requirements for reusable instruments
- device compatible with existing endoscopy stack
Procurement and contract searches
Made by procurement, materials management and finance. Almost never targeted by device manufacturers, and unusually low competition.
- gpo contract for infusion pumps
- nhs framework supplier for wound care
- total cost of ownership infusion pump comparison
- medical device distributor canada for diagnostics
Regulatory and quality searches
Made by quality, regulatory and biomedical engineering functions, and by prospective distributors assessing whether to represent you.
- iso 13485 certified device manufacturer
- eu mdr class iia requirements explained
- difference between 510k cleared and pma approved
- unique device identification labelling requirements
Service and lifecycle searches
Made by the installed base, and the strongest signal of a consumable or replacement opportunity inside an existing account.
- service contract response time for imaging equipment
- consumables compatible with legacy analyser model
- end of life support for discontinued device
- calibration interval for clinical measurement device
These are examples of how customers in this market search, drawn from keyword research and from the questions that come up on sales calls. They are illustrative, not a volume claim — the actual demand in your area is something we size before recommending anything.
The website
What the site has to do for this customer
- Market-specific product content that states regulatory status for the market being served, rather than one global description
- Indications for use published exactly as approved, and used as the source text for every downstream claim
- Instructions for use, technical specifications and compatibility lists, downloadable, dated and version-controlled
- An evidence page citing publications in full, with population, method and limitations stated rather than summarised into a headline
- Separate contact routes for clinicians, procurement, distributors and adverse event reporting, with the vigilance route obvious
- Distributor and service coverage listed by country, so a buyer can tell whether the device is available to them
- Clear labelling where content is intended for healthcare professionals only, implemented as a real control rather than a checkbox
- A documented claims and review process that the people producing content can actually see and follow
Measurement
What we report on, and what we ignore
Sessions are not on this list. These are the numbers that tell you whether the marketing is producing customers.
- Evaluation and demonstration requests from named target accounts
- Trial placements started, and the proportion converting to a purchase
- Tender and framework invitations received, and win rate against them
- Distributor-generated enquiries reported by country
- Time from first contact to committee decision, tracked by account type
- Consumable reorder rate and attachment rate across the installed base
- Service contract renewals, as the measure of an account that will buy again
- Regulatory review turnaround on marketing assets, and first-pass approval rate
Constraints
What the rules allow, and what they do not
What may be said about a device is determined by its classification and by the indications covered by its clearance, approval or certification, and that differs by market. A statement that is accurate in one country can be an unapproved claim in another, and a device that is marketed lawfully in one jurisdiction may not be promotable at all in a second. We write to the indications and status you give us and we do not extend them. Confirming what may be published, in which market, and in what wording is a decision for your regulatory affairs function — not for us, and not for a copywriter.
We do not write or imply clinical outcomes. Statements about efficacy, safety, patient benefit or comparative clinical performance belong to the approved labelling and to published evidence, cited as such. Where a study is referenced, the citation, the population, the method and the stated limitations go on the page with it, and a manufacturer-produced summary is described as exactly that. Language that suggests a result without asserting it — implication by imagery, testimonial, or a carefully vague verb — is treated as a claim and edited out.
Advertising a medical device to the general public is restricted or prohibited in a number of jurisdictions, and promotion before approval is separately restricted in most. Rules for material aimed at healthcare professionals differ again, as do requirements for disclosing sponsorship, transfers of value and clinician relationships. Audience gating, market selection and pre-approval communications need to be settled before content is planned, because they change what the page can be rather than how it is worded.
Marketing material is frequently within the scope of the quality management system. Claim review, version control, change history, approval records and archiving are auditable, so the workflow that produces a web page needs to be documented in the same way the rest of the technical file is. Practically, that means an approval record for every published asset and a scheduled re-review when labelling changes.
Content published by distributors, resellers and marketplace listings can still be attributed to the manufacturer in many markets, and translation is where claims most often drift. Written claim guidance, an approved asset library that is easier to use than writing something new, and a periodic review of partner sites are the controls that hold up in practice.
Nothing on this page is regulatory, legal or clinical advice, and none of it is a substitute for your own regulatory review. Requirements change, they differ between markets, and they turn on facts about your specific device that we are not the right people to assess. Our commitment is to work inside the boundaries your regulatory function sets, to flag anything that looks like it crosses one, and to stop rather than guess.
Questions
Questions we get from this industry
Can we publish clinical outcomes on the website?
You can publish evidence; you cannot publish conclusions the labelling does not support. The workable version is a properly referenced evidence page: the citation, the population, the method, the reported findings and the stated limitations, presented as what the study found rather than as what your device does.
What gets companies into trouble is the summarised version — a figure lifted out of a paper and turned into a headline, or a phrase that implies a benefit without asserting it. Your regulatory affairs function decides which statements are available to you in each market, and we write to that list rather than around it.
Our device is cleared in one market and not another. How does the site handle that?
With market-aware content rather than a disclaimer. That means product content that varies by market, an explicit statement of regulatory status for the market being served, and no global page describing a device in terms that are only true somewhere else.
A country selector that most visitors ignore is not a control, and neither is an interstitial that everybody clicks through. The architecture has to make the correct version the default for each market, which is a build decision to take early rather than a wording problem to patch later.
Who signs off marketing claims, and how do we stop review becoming a bottleneck?
Your regulatory and quality functions sign off. What changes the bottleneck is when they get involved, not who they are. If review is the last gate, everything arrives late and comes back rewritten.
The alternative is to agree a claim set at the start: for each market, the approved indications, the wording permitted, and the evidence supporting each statement. Content is then written from that list, and review becomes a verification step rather than a rewrite. In our experience that produces both more output and fewer problems.
Can we run paid search for a medical device?
Sometimes, and the answer depends on the device, the market and the audience. Advertising platforms apply their own restrictions and certification requirements to healthcare advertising, and those sit on top of the regulatory position rather than replacing it.
Where paid search is available, the safer and usually more productive ground is professional and procurement intent — compatibility, service, consumables, contract routes — rather than anything approaching a clinical claim. Public-facing device advertising is restricted or prohibited in a number of jurisdictions and needs a regulatory answer before a media plan.
Our distributors write their own copy. Should we be worried?
Usually yes, because in many markets responsibility for how a device is promoted follows the manufacturer regardless of who wrote the sentence. Drift is worst after translation, where a qualifier disappears and the claim quietly strengthens.
The practical controls are written claim guidance in the distributor agreement, an approved asset library in the languages they actually need, and a scheduled review of partner sites. Making approved material easier to use than writing something new solves more of this than enforcement does.
Our sales come through tenders and frameworks. What would marketing change?
Tenders decide who wins, but they rarely decide who is considered. By the time a specification is written, the people writing it have usually formed a view from evidence they found themselves, from a clinician who asked for a product by name, and from whatever your competitors published.
Marketing works upstream of that: being visible to the clinical champion, giving procurement a total-cost case they can reuse, and making sure your regulatory status and framework availability are findable. It also makes the tender response faster, because the material already exists.
Find out what is realistically winnable in your market
A strategy call is a working session on your medical device business specifically — your area, your competitors, the searches that matter and what it would take to compete for them. If we do not think we can move it, we will tell you.
If we don't deliver the work we agreed to deliver for reasons within our control, you don't pay for the undelivered work. Read our guarantee
Last updated · Reviewed by Zubair Afzal